» Articles » PMID: 35335878

Enhanced Antioxidant Effects of the Anti-Inflammatory Compound Probucol When Released from Mesoporous Silica Particles

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Mar 26
PMID 35335878
Authors
Affiliations
Soon will be listed here.
Abstract

Brain endothelial cells mediate the function and integrity of the blood brain barrier (BBB) by restricting its permeability and exposure to potential toxins. However, these cells are highly susceptible to cellular damage caused by oxidative stress and inflammation. Consequent disruption to the integrity of the BBB can lead to the pathogenesis of neurodegenerative diseases. Drug compounds with antioxidant and/or anti-inflammatory properties therefore have the potential to preserve the structure and function of the BBB. In this work, we demonstrate the enhanced antioxidative effects of the compound probucol when loaded within mesoporous silica particles (MSP) in vitro and in vivo zebrafish models. The dissolution kinetics were significantly enhanced when released from MSPs. An increased reduction in lipopolysaccharide (LPS)-induced reactive oxygen species (ROS), cyclooxygenase (COX) enzyme activity and prostaglandin E production was measured in human brain endothelial cells treated with probucol-loaded MSPs. Furthermore, the LPS-induced permeability across an endothelial cell monolayer by paracellular and transcytotic mechanisms was also reduced at lower concentrations compared to the antioxidant ascorbic acid. Zebrafish pre-treated with probucol-loaded MSPs reduced hydrogen peroxide-induced ROS to control levels after 24-h incubation, at significantly lower concentrations than ascorbic acid. We provide compelling evidence that the encapsulation of antioxidant and anti-inflammatory compounds within MSPs can enhance their release, enhance their antioxidant effects properties, and open new avenues for the accelerated suppression of neuroinflammation.

Citing Articles

Small molecule probes for peroxynitrite detection.

Grzelakowska A, Kalyanaraman B, Zielonka J Redox Biochem Chem. 2025; 10.

PMID: 39781368 PMC: 11709760. DOI: 10.1016/j.rbc.2024.100034.


Probucol will become a new model for treating cerebral infarction with a high risk of hemorrhage: A narrative review.

Lang L, Zhang J, Zheng D, Gao H Brain Circ. 2024; 9(4):222-227.

PMID: 38284116 PMC: 10821687. DOI: 10.4103/bc.bc_44_23.


Mesoporous Silica-Based Nanoplatforms Are Theranostic Agents for the Treatment of Inflammatory Disorders.

Sivamaruthi B, Thangaleela S, Kesika P, Suganthy N, Chaiyasut C Pharmaceutics. 2023; 15(2).

PMID: 36839761 PMC: 9960588. DOI: 10.3390/pharmaceutics15020439.


Mesoporous Materials as Elements of Modern Drug Delivery Systems for Anti-Inflammatory Agents: A Review of Recent Achievements.

Moritz M, Geszke-Moritz M Pharmaceutics. 2022; 14(8).

PMID: 35893798 PMC: 9331996. DOI: 10.3390/pharmaceutics14081542.

References
1.
Beckman J, Koppenol W . Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271(5 Pt 1):C1424-37. DOI: 10.1152/ajpcell.1996.271.5.C1424. View

2.
Rao R . Oxidative stress-induced disruption of epithelial and endothelial tight junctions. Front Biosci. 2008; 13:7210-26. PMC: 6261932. DOI: 10.2741/3223. View

3.
Witting P, Wu B, Raftery M, Southwell-Keely P, Stocker R . Probucol protects against hypochlorite-induced endothelial dysfunction: identification of a novel pathway of probucol oxidation to a biologically active intermediate. J Biol Chem. 2005; 280(16):15612-8. DOI: 10.1074/jbc.M414256200. View

4.
Kurose I, Kubes P, Wolf R, Anderson D, Paulson J, Miyasaka M . Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. Circ Res. 1993; 73(1):164-71. DOI: 10.1161/01.res.73.1.164. View

5.
Heeg J, Hiser M, Satonin D, Rose J . Pharmacokinetics of probucol in male rats. J Pharm Sci. 1984; 73(12):1758-63. DOI: 10.1002/jps.2600731225. View